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Background: One of the most important complications of radiotherapy (RT) for head and neck cancer (HNC) is os-
teoradionecrosis (ORN) of the jaws, arising mainly from tooth extractions. Thus, the present study aimed to evaluate 
the efficacy of leukocyte- and platelet-rich fibrin (L-PRF) in preventing ORN following tooth extraction in post-ir-
radiated HNC patients, as well as other postoperative complications.
Material and Methods: 23 patients previously submitted to conventionally fractionated 3D-conformational RT for 
HNC underwent atraumatic tooth extractions with perioperative antibiotic therapy. Besides, they were randomly as-
signed to receive L-PRF clots to fill and cover the extraction sockets (n=11, Test Group) or not (n=12, Control Group). 
A visual analog scale was used to quantify postoperative pain on the 3rd and 7th days. For ORN diagnosis, patients 
were clinically assessed for up to 180 days. Other postoperative complications (edema, alveolitis, suture dehiscence, 
continuous bleeding, and oroantral communication) were also evaluated within this period.
Results: No case of ORN or another surgical complication was observed and there were no differences in the postop-
erative pain scores between the groups on the 3rd and 7th days.
Conclusions: L-PRF did not seem to provide any additional benefits than those achieved by the combination of the 
surgical and drug protocols used for tooth extractions in the post-irradiated HNC patients.
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cal Trials Registry – ReBEC (ID RBR-8y49vf [http://
www.ensaiosclinicos.gov.br]).
Only patients requiring a single tooth extraction, 18 
years of age or older, and presenting a history of conven-
tionally fractionated 3D-conformational RT for HNC 
(cervicofacial and supraclavicular fossa fields) with to-
tal radiation dose between 60 and 70 Gy and no tumor 
local recurrence were considered eligible for inclusion 
in the study. The following exclusion criteria were also 
considered: systemic diseases or medications known 
to alter either healing processes (hard/soft tissues) or 
blood clotting, re-irradiation for recurrent tumors, and 
continuous use of medications for chronic pain.
- Study groups, clinical protocols, and procedures
Patients were randomly assigned to receive surgical and 
drug protocols either with L-PRF clots to fill and cover 
the extraction sockets (Test Group) or without it (Con-
trol Group). For that, randomization was performed us-
ing a computer-generated table and the treatment code 
for each patient was allocated into a numbered, opaque, 
sealed envelope that was opened just before surgery.
The surgical protocol consisted of extraoral antisepsis 
with aqueous-based 2% chlorhexidine and intraoral 
with aqueous-based 0.2% chlorhexidine, vasoconstric-
tor-free local anesthesia with 3% Mepivacaine, and 
atraumatic surgical technique (careful syndesomotomy, 
no mucoperiosteal divulsion and osteotomy, tooth luxa-
tion and avulsion with forceps and elevators, vigorous 
curettage and copious socket irrigation with 0.9% saline 
solution, and the X suture technique with 4-0 monofila-
ment nylon with no excessive tension). The drug rec-
ommendations were based on perioperative antibiotic 
therapy (Clindamycin 300mg every 8 hours for 10 days, 
with the first dose 3 days before the procedure) and 
postoperative pain medication, if necessary (Dipyrone 
- oral solution, 500mg every 6 hours, for up to 3 days).
- L-PRF obtaining and clot manipulation
The biomaterial was obtained moments before surgery 
by peripheral venipuncture (superficial veins of the up-
per limb). A 20 mL blood sample was collected from 
each patient through a 21G push-button blood set (Vac-
uette Safety Blood Collection Set + Luer Adapter™; 
Greiner Bio-one GmbH, Austria) with an appropriate 
holder (BD Vacutainer Single Use Holder™; BD, USA) 
into two vacuum tubes with clot activator (BD Vacu-
tainer Serum Plus Blood Collection Tubes®; BD, USA). 
Immediately after the blood collection, both vacuum 
tubes were centrifuged (Daiki DT-4000 Centrifuge™; 
Ionlab Equipamentos Laboratoriais e Hospitalares Ltda, 
Brazil) under a ≅400 g relative centrifugal force for 12 
minutes (17). L-PRF clots were then isolated and gently 
compressed using a sterile metal plate. Finally, the ex-
traction socket was filled with one clot chopped and the 
other was used to cover the wound with stabilization by 
the X suture technique (Fig. 1).
Introduction
One of the most severe, debilitating, and well-known 
complications of radiotherapy (RT) is osteoradionecro-
sis (ORN) of the jaw (1), which was first reported about 
100 years ago (2). Despite several definitions based 
mainly on clinical features, the most accepted one pro-
poses the presence of exposed devitalized irradiated 
bone that fails to heal over a period of 3-6 months (3) 
and without local tumor recurrence (4).
ORN has been declining recently thanks to technologi-
cal advances in Radiation Oncology (5) but prevalence 
rates as high as 22.9% have yet been reported (6). In 
this sense, tooth extraction is recognized as the main 
triggering factor for ORN; however, it may also occur 
spontaneously in the presence of residual foci of peri-
odontal or periapical diseases or trauma resulting from 
poorly adapted prostheses (7,8).
Platelet concentrates, biological autologous products ob-
tained from the patient’s blood, have been widely applied 
in medical areas to enhance tissue healing and stimulate 
angiogenesis due to cytokines, growth factors, and other 
proteins released by platelets (9). Leukocyte- and platelet-
rich fibrin (L-PRF), a second-generation platelet concen-
trate, has gained popularity in oral surgery also because 
of a slower, continuous release of growth factors when 
compared to other concentrates in vitro (10,11). Further-
more, the leukocytes presented in L-PRF may synthesize 
several pro- and anti-inflammatory cytokines as well (11).
On one hand, there are some promising case reports 
on the ORN treatment performed with platelet concen-
trates: 1) plasma rich in growth factors (9), 2) combina-
tion of platelet-rich plasma (PRP), alloplastic graft, and 
allogeneic dental pulp stem cells (12), 3) PRP gel (13), 
4) platelet gel (14), and 5) combination of simvastatin 
and platelet-rich fibrin (15). On the other hand, a dou-
ble-blind, split-mouth, randomized clinical trial showed 
that PRP was not effective in preventing ORN follow-
ing tooth extraction pre-RT (16).
In light of these facts and considering mainly the no-
table lack of evidence on this matter, the present study 
aims to evaluate whether the use of L-PRF could pre-
vent ORN following tooth extraction in post-irradiated 
HNC patients, as well as the occurrence of other post-
operative complications.
Material and Methods
- Study design, ethical issues, and patient recruitment
This randomized clinical trial was conducted in the Sto-
matology and Oral and Maxillofacial Surgery Center at 
Heliópolis Hospital (São Paulo, Brazil) from August 
2018 to November 2019 and adopting a convenience 
sample. The Research Ethics Committees of Ibirapuera 
University (#83264718.5.0000.5597) and Heliópolis 
Hospital (#82947318.4.0000.5449) had approved the 
study and then it was registered in the Brazilian Clini-
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- Evaluation of surgical outcomes
A visual analog scale composed of a horizontal line pre-
senting values from 0 (no pain) to 10 (the worst pain 
imaginable) and cartoon faces with different expres-
sions was given to the patients after surgery and in-
structions on it were also provided. They were asked 
about pain at the tooth extraction site on the 3rd day by 
phone call and in-person on the 7th day, during the ap-
pointment for stitch removal. Other postoperative com-
plications such as edema, alveolitis, suture dehiscence, 
continuous bleeding, and oroantral communication 
were also evaluated. For ORN diagnosis, patients were 
clinically assessed for up to 180 days.
- Data synthesis
The patients’ demographic characteristics, individual 
habits, information on oncological treatments and tu-
mors, and the tooth extraction outcomes were organized 
using the Excel™ software (Microsoft, USA) and then 
submitted to both descriptive and inferential statistical 
analyses by the Statistics Package for Social Sciences 
v21.0™ software (SPSS Inc., USA).
The Shapiro-Wilk test was used to check data distri-
bution and the Student’s T- and Chi-square tests were 
applied to identify differences between groups, with a 
P-value < 0.05 indicating statistical significance.
Results
- Sample homogeneity
Twenty-three patients were involved in the study, 
totaling 12 in the Control Group and 11 in the Test 
Group.
The average age in the Control Group was 65.5 (±10.4) 
years (range 49-82) and in the Test Group was 59.2 
(±8.1) years (range 49-79), with no statistically signifi-
cant difference (Student’s T-test; P = 0.122). Likewise, 
there was no difference (Chi-square test) between the 
groups regarding sex, skin color, tobacco use, alcohol 
use, primary tumor location, histological tumor type, 
total radiation dose, post-RT period, chemotherapy, and 
oncology surgery. Detailed data on the patients’ charac-
teristics are in Table 1 and on the oncological treatments 
and tumors in Table 2.
Fig. 1: L-PRF clot obtaining, manipulation, and surgical application. From left to right and up to down: venipuncture; blood collection; centrifu-
gation; L-PRF clot in a vacuum tube (red blood corpuscles at the bottom, platelet-poor plasma on the top, and fibrin clot in the middle); L-PRF 
clot isolated from the other blood components; L-PRF clot transferred to an especially designed kit; L-PRF clot after gentle compression; and 
a socket filled and covered with L-PRF clots.
Control Group Test Group P
Sex Female 2 (16.7%) 2 (18.2%) 0.924
Male 10 (83.3%) 9 (81.8%)
Skin color
Black 3 (25%) 2 (18.2%)
0.589Brown 3 (25%) 5 (45.5%)
White 6 (50%) 4 (36.4%)
Tobacco use
Current 2 (16.7%) 3 (27.3%)
0.361Previous 6 (50%) 7 (63.6%)
No 4 (33.3%) 1 (9.1%)
Alcohol use
Current 3 (25%) 2 (18.2%)
0.925Previous 7 (58.3%) 7 (63.6%)
No 2 (16.7%) 2 (18.2%)
There was no statistically significant difference between groups (Chi-square test).
Table 1: Patients’ additional data.
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- Surgical procedures and outcomes
Eight upper (66.7%) and 4 lower teeth (33.3%) were ex-
tracted in the Control Group and 4 upper (36.4%) and 7 
lower teeth (63.6%) in the Test Group, with no statisti-
cally significant difference (Chi-square test; P = 0.537). 
More information on the tooth extraction sites is pre-
sented in Table 3.
Only one patient from the Test Group experienced 
postoperative pain on the 3rd day, reporting a score of 
2. Anyway, no difference between the groups was ob-
tained as well (Student’s T-test; P = 0.307).
No case of ORN development and postoperative com-
plications was identified in any patient. The surgical 
outcomes are shown in detail in Table 4.
Control Group Test Group P
Primary tumor location
Larynx 5 (41.7%) 3 (27.3%)
0.105
Oral cavity 1 (8.3%) 5 (45.5%)
Parotid gland 0 (0%) 1 (9.1%)
Pharynx 6 (50%) 2 (18.2%)
Histological tumor type
Carcinoma ex pleomorphic adenoma 0 (0%) 1 (9.1%)
0.286
Squamous cell carcinoma 12 (100%) 10 (90.9%)
Total radiation dose
60-65 Gy 3 (25%) 4 (36.4%)
0.65266-69 Gy 4 (33.3%) 4 (36.4%)
70 Gy 5 (41.7%) 3 (27.3%)
Post-radiotherapy period
Up to a year 1 (8.3%) 1 (9.1%)
0.161
1-3 years 1 (8.3%) 4 (36.4%)
3-5 years 1 (8.3%) 3 (27.3%)
5-7 years 3 (25%) 0 (0%)
7-9 years 2 (16.7%) 0 (0%)
Over 9 years 4 (33.3%) 3 (27.3%)
Chemotherapy
Yes 5 (41.7%) 6 (54.5%)
0.537
No 7 (58.3%) 5 (45.5%)
Oncologic surgery
Yes 6 (50%) 7 (63.6%)
0.510
No 6 (50%) 4 (36.4%)
There was no statistically significant difference between groups (Chi-square test).
Table 2: Patients’ tumors and oncologic treatments.
Control Group Test Group
Maxillae
Incisives 1 (8.3%) 2 (18.2%)
Canines 0 (0%) 0 (0%)
Premolars 3 (25%) 1 (9.1%)
Molars 4 (33.3%) 1 (9.1%)
Mandible
Incisives 2 (16.7%) 3 (27.3%)
Canines 0 (0%) 0 (0%)
Premolars 0 (0%) 0 (0%)
Molars 2 (16.7%) 4 (36.4%)
There was no statistically significant difference between groups 
(Chi-square test; P = 0.537).
Table 3: Tooth extraction sites.
Control Group Test Group P
Osteoradionecrosis development
Yes 0 (0%) 0 (0%)
-
No 12 (100%) 11 (100%)
Postoperative complications
Yes 0 (0%) 0 (0%)
-
No 12 (100%) 11 (100%)
Mean pain score
3rd day 0 (±0) 0.2 (±0.6) 0.307
7th day 0 (±0) 0 (±0) -
There was no statistically significant difference between groups (Student’s T-test).
Table 4: Surgical outcomes.
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Discussion
The present study aimed at investigating the use of L-
PRF in tooth extraction sites of HNC patients post-RT, 
considering ORN development and other postoperative 
complications. The results from both study groups were 
highly satisfactory and may be considered of great clin-
ical relevance due to the difficulties in the treatment of 
ORN and the related symptoms (e.g., localized mild al-
gesia, dysesthesia, halitosis, severe pain, orocutaneous 
fistulas, and even pathological fractures) (18).
The design and hypothesis of the current study were 
mainly based on the likely benefits of L-PRF for ordi-
nary tooth extractions in healthy patients: soft tissue 
and bone healing improvement, inflammation control, 
and postoperative pain reduction (19). These effects are 
thought to occur as L-PRF is a rich source of growth 
factors, cytokines, and other proteins (e.g., transform-
ing growth factor β, platelet-derived growth factor, and 
vascular endothelial growth factor), which may impact 
positively on healing processes such as angiogenesis 
and immune control (20). Moreover, L-PRF seems to 
induce and stimulate the proliferation of osteoblasts, fi-
broblasts, and keratinocytes, as well as to promote an 
important differentiation of osteoblasts (19). Further 
advantages include mechanical protection to surgical 
wounds, ease of preparation and manipulation, and low 
cost (20).
Considering the probable role of microorganisms in 
ORN pathophysiology, perioperative systemic antibi-
otic administration might be rationale and was adopt-
ed here as a protocol; however, several different drug 
regimens and success rates have already been reported 
in the literature (8,21). Although there has been not 
enough evidence to support the prevention of alveolitis 
and infections in non-irradiated patients and taking into 
account all possible adverse effects, any minor clinical 
benefit would justify the use of prophylactic antibiotic 
therapy because of ORN morbidity and severity (22). 
Moreover, antibiotics are easy to administer and widely 
available (7).
Despite the conflicting results of other studies and a 
slight preference for a drug from the penicillin family 
due to the affectivity against most oral bacteria (22), 
clindamycin was administered. It is active against most 
strains of Staphylococcus aureus, several other gram-
positive cocci, and gram-negative anaerobic pathogens 
(23), and is a good option for β-lactam-allergic patients. 
Clindamycin also provides good penetration into bone 
tissue, has been historically successful in the treatment 
of osteomyelitis (23), and is available for free in the Bra-
zilian Public Health System.
Atraumatic surgical technique, alveoloplasty to remove 
bone spicules, primary wound closure without tension, 
a reduced number of teeth extracted per session (24), 
minimal periosteum divulsion, vasoconstrictor-free lo-
cal anesthesia, and mouthwashes with chlorhexidine 
have been proposed as preventive factors for ORN 
following tooth extractions (8). Most of them were ap-
plied in this study, except for alveoloplasty and primary 
wound closure (avoiding periosteal divulsion or exces-
sive tension at the edges) and mouthwashes with anti-
septic solutions (aiding to maintain clot stability into the 
extraction sockets and the L-PRF clots over the surgical 
wounds).
To the best of the authors’ knowledge, there is no simi-
lar study on L-PRF in combination or not with surgical 
and drug protocols for tooth extractions in HNC pa-
tients post-RT. Although the current results are encour-
aging, they should be interpreted with caution mainly 
because of the limited sample size. Likewise, some fac-
tors that would increase the risk of ORN such as the pe-
riod between RT completion and tooth extraction (25), 
concomitant chemotherapy (26), current alcohol and 
tobacco use (4,5), and the lack of accurate data on the 
total radiation dose delivered to each tooth extraction 
site (21) can be considered study bias.
The authors, however, in an attempt to mitigate the 
discrepancy among demographic characteristics of the 
study individuals, recruited only those who underwent 
conventionally fractionated 3D-conformal RT with 
cervicofacial and supraclavicular fossa fields, giving 
strong evidence that the extraction sites received sub-
stantial radiation total doses. As such, patients submit-
ted to other techniques (e.g., hyperfractioned regimen, 
brachytherapy, intensity-modulated RT) were not con-
sidered for the analyses. Furthermore, the lack of any 
statistically significant difference between both groups 
regarding the patients’ variables indicates an adequate 
sample homogeneity.
In summary, within the limitations of this study, the use 
of L-PRF in tooth extractions for HNC patients post-RT 
did not seem to offer any additional benefit over to the 
surgical and drug protocols proposed.
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